The need for identifying standardized indices for measuring glucose variability.

Corresponding Author: Simona Frontoni, M.D., Ph.D., Endocrinology Diabetes and Metabolism S. Giovanni Calibita Fatebenefratelli Hospital, Department of Internal Medicine, University of Rome Tor Vergata, Via Montpeller 1 00133 Rome, Italy; email address [email protected] We read the article by Siegelaar and colleagues,1 which clearly suggests the lack of association between glycemic variability (GV) and oxidative stress estimated by 8-iso-prostaglandin F2α (8-iso-PGF2α) excretion rate in patients with type 2 diabetes mellitus (T2DM) with good metabolic control by oral glucose lowering agents. We have, however, some concerns.